• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

食物对乌干达成年人中替诺福韦、恩曲他滨联合依非韦伦稳态药代动力学的影响。

Effect of Food on the Steady-State Pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan Adults.

作者信息

Lamorde Mohammed, Byakika-Kibwika Pauline, Tamale William S, Kiweewa Francis, Ryan Mairin, Amara Alieu, Tjia John, Back David, Khoo Saye, Boffito Marta, Kityo Cissy, Merry Concepta

机构信息

Infectious Diseases Institute, Makerere University, College of Health Sciences, P.O. Box 22418, Kampala, Uganda.

出版信息

AIDS Res Treat. 2012;2012:105980. doi: 10.1155/2012/105980. Epub 2012 Feb 20.

DOI:10.1155/2012/105980
PMID:22454762
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3290802/
Abstract

We investigated the effect of food on the steady-state pharmacokinetics of a proprietary fixed-dose combination (FDC) tablet containing tenofovir disoproxil fumarate (TDF)/emtricitabine/efavirenz. Fifteen Ugandan HIV-1 patients at steady-state dosing with TDF/emtricitabine/efavirenz were admitted for 24-hour intensive pharmacokinetic sampling after dosing in the fasting state. Blood sampling was repeated seven days later with TDF/emtricitabine/efavirenz administered with food (19 g fat). Drug concentrations in plasma were determined by liquid chromatography and tandem mass spectrometry. Geometric mean ratios (GMRs) and confidence intervals (CIs) of parameters were calculated (reference, fasting). For efavirenz, GMRs (90% CIs) for C(max), AUC(0-24), and C(24) were 1.47 (1.24-1.75), 1.13 (1.03-1.23), and 1.01 (0.91-1.11), respectively. Corresponding GMRs were 1.04 (0.84-1.27), 1.19 (1.10-1.29), and 0.99 (0.82-1.19) for tenofovir, 0.83 (0.76-0.92), 0.87 (0.78-0.97), and 0.91 (0.73-1.14) for emtricitabine. Stable patients may take the FDC without meal restrictions. The FDC should be taken without food by patients experiencing central nervous system toxicities.

摘要

我们研究了食物对一种含有富马酸替诺福韦二吡呋酯(TDF)/恩曲他滨/依非韦伦的专利固定剂量复方(FDC)片剂稳态药代动力学的影响。15名接受TDF/恩曲他滨/依非韦伦稳态给药的乌干达HIV-1患者在禁食状态下给药后入院进行24小时强化药代动力学采样。7天后,在给予TDF/恩曲他滨/依非韦伦并同时进食(19克脂肪)的情况下重复采血。采用液相色谱和串联质谱法测定血浆中的药物浓度。计算参数的几何平均比值(GMRs)和置信区间(CIs)(参考值,禁食)。对于依非韦伦,C(max)、AUC(0 - 24)和C(24)的GMRs(90% CIs)分别为1.47(1.24 - 1.75)、1.13(1.03 - 1.23)和1.01(0.91 - 1.11)。替诺福韦的相应GMRs为1.04(0.84 - 1.27)、1.19(1.10 - 1.29)和0.99(0.82 - 1.19),恩曲他滨的相应GMRs为0.83(0.76 - 0.92)、0.87(0.78 - 0.97)和0.91(0.73 - 1.14)。病情稳定的患者服用该FDC时无需限制饮食。出现中枢神经系统毒性的患者服用该FDC时应空腹。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c31f/3290802/2372c8abf292/ART2012-105980.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c31f/3290802/8e300692be24/ART2012-105980.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c31f/3290802/2372c8abf292/ART2012-105980.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c31f/3290802/8e300692be24/ART2012-105980.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c31f/3290802/2372c8abf292/ART2012-105980.002.jpg

相似文献

1
Effect of Food on the Steady-State Pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan Adults.食物对乌干达成年人中替诺福韦、恩曲他滨联合依非韦伦稳态药代动力学的影响。
AIDS Res Treat. 2012;2012:105980. doi: 10.1155/2012/105980. Epub 2012 Feb 20.
2
Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults.在乌干达感染HIV-1的成年患者中,不同用餐条件下利匹韦林的稳态药代动力学
J Antimicrob Chemother. 2015 May;70(5):1482-6. doi: 10.1093/jac/dku575. Epub 2015 Feb 3.
3
Bioequivalence of efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen.依非韦伦/恩曲他滨/富马酸替诺福韦二吡呋酯单片复方制剂的生物等效性
J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):167-73. doi: 10.1097/QAI.0b013e3181427835.
4
Pharmacokinetics of Co-Formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate After Switch From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects.健康受试者从依非韦伦/恩曲他滨/替诺福韦酯转换为复方制剂埃替拉韦/考比司他/恩曲他滨/替诺福韦酯富马酸盐后的药代动力学
J Acquir Immune Defic Syndr. 2016 Jul 1;72(3):281-8. doi: 10.1097/QAI.0000000000000959.
5
Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.随机、2 期评价两种单一片剂方案:艾维雷韦/考比司他/恩曲他滨/替诺福韦富马酸酯与依非韦伦/恩曲他滨/替诺福韦富马酸酯用于初治 HIV 感染。
AIDS. 2011 Mar 27;25(6):F7-12. doi: 10.1097/QAD.0b013e328345766f.
6
Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial.多替拉韦与恩曲他滨和富马酸替诺福韦艾拉酚胺或富马酸替诺福韦二吡呋酯,以及依非韦伦、恩曲他滨和富马酸替诺福韦二吡呋酯用于孕期启动的HIV抗逆转录病毒治疗方案的疗效和安全性(IMPAACT 2010/VESTED):一项多中心、开放标签、随机、对照、3期试验。
Lancet. 2021 Apr 3;397(10281):1276-1292. doi: 10.1016/S0140-6736(21)00314-7.
7
Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment.在初治的HIV-1感染成年患者中,进行的rilpivirine/恩曲他滨/富马酸替诺福韦二吡呋酯单一片剂方案(STaR)试验与依法韦仑/恩曲他滨/富马酸替诺福韦二吡呋酯对比,治疗48周的患者报告结局。
AIDS Care. 2016;28(3):401-8. doi: 10.1080/09540121.2015.1096890. Epub 2015 Oct 21.
8
Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.从依非韦伦、恩曲他滨和富马酸替诺福韦二吡呋酯转换为替诺福韦艾拉酚胺与利匹韦林和恩曲他滨联合复方制剂用于治疗 HIV-1 感染病毒抑制成人:一项随机、双盲、多中心、3b 期、非劣效性研究。
Lancet HIV. 2017 May;4(5):e205-e213. doi: 10.1016/S2352-3018(17)30032-2. Epub 2017 Mar 2.
9
Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.多替拉韦加拉米夫定与恩曲他滨和丙酚替诺福韦艾拉酚胺或富马酸替诺福韦二吡呋酯对比依非韦伦、恩曲他滨和富马酸替诺福韦二吡呋酯,用于治疗人类免疫缺陷病毒 1 型感染的初始治疗(ADVANCE):一项随机、3 期、非劣效性试验的第 96 周结果。
Lancet HIV. 2020 Oct;7(10):e666-e676. doi: 10.1016/S2352-3018(20)30241-1.
10
Effect of food on rilpivirine/emtricitabine/tenofovir disoproxil fumarate, an antiretroviral single-tablet regimen for the treatment of HIV infection.食物对rilpivirine/恩曲他滨/替诺福韦酯富马酸盐(一种用于治疗HIV感染的抗逆转录病毒单片复方制剂)的影响。
J Clin Pharmacol. 2014 Apr;54(4):378-85. doi: 10.1002/jcph.210. Epub 2013 Nov 16.

引用本文的文献

1
Clinical trial simulation to evaluate tenofovir disoproxil fumarate/emtricitabine HIV pre-exposure prophylaxis dosing during pregnancy.评估替诺福韦酯/恩曲他滨用于孕期HIV暴露前预防给药的临床试验模拟
Front Reprod Health. 2023 Sep 27;5:1224580. doi: 10.3389/frph.2023.1224580. eCollection 2023.
2
Interactions of Antiretroviral Drugs with Food, Beverages, Dietary Supplements, and Alcohol: A Systematic Review and Meta-analyses.抗逆转录病毒药物与食物、饮料、膳食补充剂和酒精的相互作用:系统评价和荟萃分析。
AIDS Behav. 2023 May;27(5):1441-1468. doi: 10.1007/s10461-022-03880-6. Epub 2022 Nov 1.
3
Design, Optimization, Manufacture and Characterization of Efavirenz-Loaded Flaxseed Oil Nanoemulsions.

本文引用的文献

1
Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study.CYP2B6、ABCB1 和 CYP3A5 多态性对依非韦伦药代动力学和治疗反应的影响:一项艾滋病临床治疗试验组研究。
J Infect Dis. 2010 Sep 1;202(5):717-22. doi: 10.1086/655470.
2
Food insecurity as a barrier to sustained antiretroviral therapy adherence in Uganda.在乌干达,食物不安全是持续抗逆转录病毒治疗依从性的障碍。
PLoS One. 2010 Apr 28;5(4):e10340. doi: 10.1371/journal.pone.0010340.
3
Bioequivalence of efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen.
依法韦仑负载亚麻籽油纳米乳剂的设计、优化、制备与表征
Pharmaceutics. 2020 Aug 23;12(9):797. doi: 10.3390/pharmaceutics12090797.
4
Longitudinal change in bone mineral density among Chinese individuals with HIV after initiation of antiretroviral therapy.开始抗逆转录病毒治疗后,中国 HIV 感染者的骨密度纵向变化。
Osteoporos Int. 2021 Feb;32(2):321-332. doi: 10.1007/s00198-020-05584-w. Epub 2020 Aug 15.
5
The Potential of Long-Acting, Tissue-Targeted Synthetic Nanotherapy for Delivery of Antiviral Therapy Against HIV Infection.长效、组织靶向的合成纳米治疗在递送抗 HIV 感染抗病毒治疗中的潜力。
Viruses. 2020 Apr 7;12(4):412. doi: 10.3390/v12040412.
6
The Increase of HIV-1 Infection, Neurocognitive Impairment, and Type 2 Diabetes in The Rio Grande Valley.里奥格兰德河谷地区 HIV-1 感染、神经认知障碍和 2 型糖尿病的增加。
Curr HIV Res. 2019;17(6):377-387. doi: 10.2174/1570162X17666191029162235.
7
Physiologically Based Pharmacokinetic Models to Predict Maternal Pharmacokinetics and Fetal Exposure to Emtricitabine and Acyclovir.基于生理学的药代动力学模型预测恩曲他滨和阿昔洛韦在母体中的药代动力学和胎儿暴露情况。
J Clin Pharmacol. 2020 Feb;60(2):240-255. doi: 10.1002/jcph.1515. Epub 2019 Sep 6.
8
Knowledge, attitudes, perception and practices regarding antiretroviral therapy among HIV-infected adults in Antananarivo, Madagascar: a cross-sectional survey.马达加斯加塔那那利佛市感染艾滋病毒的成年人对抗逆转录病毒疗法的知识、态度、认知及实践:一项横断面调查
BMC Health Serv Res. 2019 May 28;19(1):341. doi: 10.1186/s12913-019-4173-3.
9
Recent developments of nanotherapeutics for targeted and long-acting, combination HIV chemotherapy.针对 HIV 化疗的靶向和长效联合的纳米治疗学的最新进展。
Eur J Pharm Biopharm. 2019 May;138:75-91. doi: 10.1016/j.ejpb.2018.04.014. Epub 2018 Apr 17.
10
The Effect of Food on Doravirine Bioavailability: Results from Two Pharmacokinetic Studies in Healthy Subjects.食物对多韦拉韦生物利用度的影响:两项健康受试者药代动力学研究的结果。
Clin Drug Investig. 2017 Jun;37(6):571-579. doi: 10.1007/s40261-017-0512-5.
依非韦伦/恩曲他滨/富马酸替诺福韦二吡呋酯单片复方制剂的生物等效性
J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):167-73. doi: 10.1097/QAI.0b013e3181427835.
4
Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals.依法韦仑对HIV感染者神经心理表现及症状的影响。
Ann Intern Med. 2005 Nov 15;143(10):714-21. doi: 10.7326/0003-4819-143-10-200511150-00008.
5
Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.依非韦伦的药物遗传学与中枢神经系统副作用:成人艾滋病临床试验组研究
AIDS. 2004 Dec 3;18(18):2391-400.
6
Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics.替诺福韦酯:临床药理学与药代动力学
Clin Pharmacokinet. 2004;43(9):595-612. doi: 10.2165/00003088-200443090-00003.
7
Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.依法韦仑的血浆水平可预测HIV-1感染患者的治疗失败及中枢神经系统副作用。
AIDS. 2001 Jan 5;15(1):71-5. doi: 10.1097/00002030-200101050-00011.
8
Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection.用于治疗HIV感染患者的抗逆转录病毒药物的药代动力学及潜在相互作用。
Clin Pharmacokinet. 1999 Apr;36(4):289-304. doi: 10.2165/00003088-199936040-00004.
9
Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxycarbonyloxymethyl)-9-(2-phosphonylmethoxypropyl)adenine in mice.口服双(异丙氧基羰氧基甲基)-9-(2-膦酰甲氧基丙基)腺嘌呤在小鼠体内的抗逆转录病毒疗效和药代动力学
Antimicrob Agents Chemother. 1998 Jul;42(7):1568-73. doi: 10.1128/AAC.42.7.1568.